Fusion Antibodies (FAB) Competitors

Fusion Antibodies logo
GBX 4 -0.25 (-5.88%)
As of 03:39 AM Eastern

FAB vs. OKYO, IMM, AOR, OBD, and NSCI

Should you buy Fusion Antibodies stock or one of its competitors? Fusion Antibodies's main competitors and comparable companies include OKYO Pharma (OKYO), ImmuPharma (IMM), AorTech International (AOR), Oxford BioDynamics (OBD), and NetScientific (NSCI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Fusion Antibodies compare to OKYO Pharma?

Fusion Antibodies (LON:FAB) and OKYO Pharma (LON:OKYO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

In the previous week, Fusion Antibodies had 1 more articles in the media than OKYO Pharma. MarketBeat recorded 1 mentions for Fusion Antibodies and 0 mentions for OKYO Pharma. Fusion Antibodies' average media sentiment score of 0.00 equaled OKYO Pharma'saverage media sentiment score.

Company Overall Sentiment
Fusion Antibodies Neutral
OKYO Pharma Neutral

15.8% of Fusion Antibodies shares are owned by institutional investors. 6.4% of Fusion Antibodies shares are owned by company insiders. Comparatively, 31.9% of OKYO Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

OKYO Pharma has a net margin of 0.00% compared to Fusion Antibodies' net margin of -54.45%. Fusion Antibodies' return on equity of -97.87% beat OKYO Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-54.45% -97.87% -63.78%
OKYO Pharma N/A -397.13%-154.72%

Fusion Antibodies has a beta of 1.244, suggesting that its share price is 24% more volatile than the broader market. Comparatively, OKYO Pharma has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

Fusion Antibodies has higher revenue and earnings than OKYO Pharma. Fusion Antibodies is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£2.11M2.37-£4.10M-£1.00N/A
OKYO PharmaN/AN/A-£6.70M-£0.01N/A

Summary

Fusion Antibodies beats OKYO Pharma on 8 of the 11 factors compared between the two stocks.

How does Fusion Antibodies compare to ImmuPharma?

Fusion Antibodies (LON:FAB) and ImmuPharma (LON:IMM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

ImmuPharma has lower revenue, but higher earnings than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£2.11M2.37-£4.10M-£1.00N/A
ImmuPharmaN/AN/A-£2.51M-£0.83N/A

Fusion Antibodies has a beta of 1.244, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, ImmuPharma has a beta of 3.017, suggesting that its stock price is 202% more volatile than the broader market.

In the previous week, Fusion Antibodies had 1 more articles in the media than ImmuPharma. MarketBeat recorded 1 mentions for Fusion Antibodies and 0 mentions for ImmuPharma. Fusion Antibodies' average media sentiment score of 0.00 equaled ImmuPharma'saverage media sentiment score.

Company Overall Sentiment
Fusion Antibodies Neutral
ImmuPharma Neutral

15.8% of Fusion Antibodies shares are owned by institutional investors. Comparatively, 6.1% of ImmuPharma shares are owned by institutional investors. 6.4% of Fusion Antibodies shares are owned by insiders. Comparatively, 6.2% of ImmuPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

ImmuPharma has a net margin of 3,519.56% compared to Fusion Antibodies' net margin of -54.45%. Fusion Antibodies' return on equity of -97.87% beat ImmuPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-54.45% -97.87% -63.78%
ImmuPharma 3,519.56%-559.87%-43.00%

Summary

ImmuPharma beats Fusion Antibodies on 6 of the 11 factors compared between the two stocks.

How does Fusion Antibodies compare to AorTech International?

Fusion Antibodies (LON:FAB) and AorTech International (LON:AOR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

In the previous week, Fusion Antibodies had 1 more articles in the media than AorTech International. MarketBeat recorded 1 mentions for Fusion Antibodies and 0 mentions for AorTech International. Fusion Antibodies' average media sentiment score of 0.00 equaled AorTech International'saverage media sentiment score.

Company Overall Sentiment
Fusion Antibodies Neutral
AorTech International Neutral

15.8% of Fusion Antibodies shares are owned by institutional investors. 6.4% of Fusion Antibodies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

AorTech International has lower revenue, but higher earnings than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than AorTech International, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£2.11M2.37-£4.10M-£1.00N/A
AorTech International£539K0.00N/A-£3.70N/A

AorTech International has a net margin of 0.00% compared to Fusion Antibodies' net margin of -54.45%. AorTech International's return on equity of 0.00% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-54.45% -97.87% -63.78%
AorTech International N/A N/A N/A

Summary

Fusion Antibodies beats AorTech International on 6 of the 9 factors compared between the two stocks.

How does Fusion Antibodies compare to Oxford BioDynamics?

Oxford BioDynamics (LON:OBD) and Fusion Antibodies (LON:FAB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Fusion Antibodies has higher revenue and earnings than Oxford BioDynamics. Fusion Antibodies is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford BioDynamics£1.20M11.36-£103.52M-£0.20N/A
Fusion Antibodies£2.11M2.37-£4.10M-£1.00N/A

Fusion Antibodies has a net margin of -54.45% compared to Oxford BioDynamics' net margin of -825.61%. Fusion Antibodies' return on equity of -97.87% beat Oxford BioDynamics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford BioDynamics-825.61% -451.74% -56.23%
Fusion Antibodies -54.45%-97.87%-63.78%

11.7% of Oxford BioDynamics shares are held by institutional investors. Comparatively, 15.8% of Fusion Antibodies shares are held by institutional investors. 53.2% of Oxford BioDynamics shares are held by insiders. Comparatively, 6.4% of Fusion Antibodies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Fusion Antibodies had 1 more articles in the media than Oxford BioDynamics. MarketBeat recorded 1 mentions for Fusion Antibodies and 0 mentions for Oxford BioDynamics. Oxford BioDynamics' average media sentiment score of 0.76 beat Fusion Antibodies' score of 0.00 indicating that Oxford BioDynamics is being referred to more favorably in the media.

Company Overall Sentiment
Oxford BioDynamics Positive
Fusion Antibodies Neutral

Oxford BioDynamics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.244, indicating that its stock price is 24% more volatile than the broader market.

Summary

Fusion Antibodies beats Oxford BioDynamics on 7 of the 13 factors compared between the two stocks.

How does Fusion Antibodies compare to NetScientific?

NetScientific (LON:NSCI) and Fusion Antibodies (LON:FAB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Fusion Antibodies has a net margin of -54.45% compared to NetScientific's net margin of -182.91%. NetScientific's return on equity of -13.70% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
NetScientific-182.91% -13.70% -9.42%
Fusion Antibodies -54.45%-97.87%-63.78%

In the previous week, Fusion Antibodies had 1 more articles in the media than NetScientific. MarketBeat recorded 1 mentions for Fusion Antibodies and 0 mentions for NetScientific. NetScientific's average media sentiment score of 0.00 equaled Fusion Antibodies'average media sentiment score.

Company Overall Sentiment
NetScientific Neutral
Fusion Antibodies Neutral

14.7% of NetScientific shares are owned by institutional investors. Comparatively, 15.8% of Fusion Antibodies shares are owned by institutional investors. 42.4% of NetScientific shares are owned by company insiders. Comparatively, 6.4% of Fusion Antibodies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

NetScientific has higher earnings, but lower revenue than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than NetScientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NetScientific£1.45M0.00-£2.64M-£0.11N/A
Fusion Antibodies£2.11M2.37-£4.10M-£1.00N/A

NetScientific has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.244, indicating that its stock price is 24% more volatile than the broader market.

Summary

NetScientific beats Fusion Antibodies on 6 of the 11 factors compared between the two stocks.

Get Fusion Antibodies News Delivered to You Automatically

Sign up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FAB vs. The Competition

MetricFusion AntibodiesBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£5.01M£4.02B£7.72B£2.74B
Dividend YieldN/A3.63%2.47%5.11%
P/E Ratio-4.0026.5432.9523.17
Price / Sales2.3715.698.215.06
Price / Cash9.0222.7220.8520.23
Price / Book1.144.164.432.46
Net Income-£4.10M-£23.99M£3.51B£5.88B
7 Day Performance-4.76%-5.89%-4.73%-1.74%
1 Month Performance-31.21%-7.78%-5.69%-3.52%
1 Year Performance-67.65%-5.69%-1.18%6.90%

Fusion Antibodies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FAB
Fusion Antibodies
N/AGBX 4
-5.9%
N/A-67.8%£5.01M£2.11MN/A24
OKYO
OKYO Pharma
N/AN/AN/AN/A£23.24MN/AN/A7
IMM
ImmuPharma
N/AGBX 3.24
-2.0%
N/A-72.3%£20.23MN/AN/A13
AOR
AorTech International
N/AN/AN/AN/A£19.99M£539KN/A3
OBD
Oxford BioDynamics
N/AGBX 0.11
flat
N/A-63.3%£14.79M£1.20MN/A45

Related Companies and Tools


This page (LON:FAB) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners